contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


extraordinary-general-meeting-in-cantargia-ab-publ-3

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Cantargia is a pharmaceutical company. Today, there is specialization in the development of antibody drugs used in the treatment of leukemia and other cancers such as lung and pancreatic cancer. The company's objective is to develop, sell and license drug candidates to companies operating in the mentioned work area. The largest operations are in the Nordic market, with headquarters in Lund.

Cantargia

Cantargia’s extraordinary general meeting on December 2, 2024, resolved to approve the board’s resolution from November 6, 2024 to increase the company’s share capital through the issuance of...

<div class="mfn-preamble"><p><strong>Cantargia’s extraordinary general meeting on December 2, 2024, resolved to approve the board’s resolution from November 6, 2024 to increase the company’s share capital through the issuance of new shares with pre-emptive rights for the company’s shareholders. Subscription may also be made without pre-emptive rights, as set forth in the complete issue resolution.</strong></p></div><div class="mfn-body"><p>Through the rights issue, Cantargia’s share capital will increase with not more than SEK 7,347,467.36, through the issue of not more than 91,843,342 new shares.</p><p>The record date for the right to participate in the rights issue is December 4, 2024. Two existing shares held on the record date, entitle to subscription for one new share. The subscription price is SEK 1.85 per share.</p><p>For further details and information about the background and reasons for the rights issue, see Cantargia’s press release on November 6, 2024.</p></div><div class="mfn-footer mfn-contacts mfn-47db31b9c771"><p><strong class="mfn-heading-1">For further information, please contact</strong><br>Göran Forsberg, CEO<br>Telephone: +46 (0)46-275 62 60<br>E-mail: <a rel="noopener" href="mailto:goran.forsberg@cantargia.com">goran.forsberg@cantargia.com</a></p></div><div class="mfn-footer mfn-about mfn-1508b27957df"><p><strong class="mfn-heading-1">About Cantargia</strong><br>Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia’s oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia’s second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on hidradenitis suppurativa and systemic sclerosis.<br>&nbsp;<br>Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at&nbsp;<a rel="noopener" href="https://cantargia.com/en">www.cantargia.com</a>.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/c0896694-ae51-4e99-ad5c-94dc347faa8e/extraordinary-general-meeting-in-cantargia-ab-publ.pdf" class="mfn-generated mfn-primary">Extraordinary general meeting in Cantargia AB (publ)</a></p></div>

Extraordinary general meeting in Cantargia AB (publ)

Federal Reserven korkopäätös: Kiire loppui tähän

Lääkekehityssijoittaminen: Arvonluonti yrityskaupoilla ja lisensointisopimuksilla

EKP:n korkopäätös: Keskuspankki ilman rajoitteita

Euroalueen ostopäälliköt: Onks sen jälkeen vielä mäki?

Laskuviikko takana Euroopassa, EKP:n viesti sai lopulta velkakirjakorot nousuun

Pysy ajantasalla Inderesin uutiskirjeillä